Gene-expression prognostic assays
Tests that measure a set of genes in a removed tumour to estimate how likely it is to come back, so patients with low scores can safely skip chemotherapy.
Overview
Multigene expression assays run on resected tumour tissue estimate recurrence risk and, for some, chemotherapy benefit. Oncotype DX (21 genes) and MammaPrint (70 genes) are the best known in breast cancer, where the TAILORx and MINDACT trials showed that most women with low scores gain nothing from chemotherapy; Prolaris and Decipher serve the same purpose in prostate cancer. They are recommended in major guidelines and reimbursed in many systems.
How it works
RNA is extracted from fixed tumour tissue and the expression of a fixed gene panel is measured by RT-PCR or microarray and combined into a validated risk score.
- Prospective trial evidence for de-escalating chemotherapy
- Standard of care in early hormone-positive breast cancer
- Adds to clinical and pathological factors
- Cost and turnaround
- Validated mainly in specific subtypes and stages
- Scores near thresholds remain hard to act on
Latest papers
topQuery for this technology: (TITLE:"Gene-expression prognostic assays" OR ABSTRACT:"Gene-expression prognostic assays") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Gene-expression prognostic assays, not a curated reading list.
Similar pages
not linked directly; found by shared links- PairingGene-expression assay → chemotherapy omission
Shares MammaPrint (70-gene signature), Oncotype DX, HR-positive / HER2-negative breast cancer.
- TreatmentProsigna (PAM50)
Shares MammaPrint (70-gene signature), Oncotype DX, HR-positive / HER2-negative breast cancer.
- CompanyAgendia
Shares MammaPrint (70-gene signature), HR-positive / HER2-negative breast cancer.
- TrialMINDACT
Shares MammaPrint (70-gene signature), HR-positive / HER2-negative breast cancer.
- PersonKevin Kalinsky
Shares Oncotype DX, HR-positive / HER2-negative breast cancer.
- PersonRené Bernards
Shares MammaPrint (70-gene signature), HR-positive / HER2-negative breast cancer.
- CompanyMyriad Genetics
Shares Prolaris, Prostate cancer, HR-positive / HER2-negative breast cancer.
- PersonJoseph A. Sparano
Shares Oncotype DX, HR-positive / HER2-negative breast cancer.